(Q38866152)

7 September 2017

1 reference

title

Biologics in Pediatric Rheumatology: Quo Vadis? (English)

1 reference

7 September 2017

Yonit Sterba

1

1 reference

7 September 2017

Norman Ilowite

series ordinal

2

1 reference

7 September 2017

publication date

1 July 2016

1 reference

Current Rheumatology Reports

7 September 2017

published in

1 reference

7 September 2017

volume

18

1 reference

7 September 2017

issue

7

1 reference

7 September 2017

page(s)

45

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-016-0593-9

7 September 2017

exact match

0 references

cites work

Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Malignancies in juvenile idiopathic arthritis: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11926-016-0593-9

Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis

21 January 2018

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry

1 reference

12 December 2020

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis

1 reference

12 December 2020

Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes

1 reference

12 December 2020

10.1007/S11926-016-0593-9

Identifiers

DOI

1 reference

Dimensions Publication ID

7 September 2017

1002605030

0 references

1 reference